Jeong Hyeok Yoon
Soongsil University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jeong Hyeok Yoon.
Journal of Biological Chemistry | 2010
Hye Jin Jung; Joong Sup Shim; Jiyong Lee; Young Mi Song; Ki Chung Park; Seung Hoon Choi; Nam Doo Kim; Jeong Hyeok Yoon; Paul T. Mungai; Paul T. Schumacker; Ho Jeong Kwon
Cellular oxygen sensing is required for hypoxia-inducible factor-1α stabilization, which is important for tumor cell survival, proliferation, and angiogenesis. Here we find that terpestacin, a small molecule previously identified in a screen of microbial extracts, binds to the 13.4-kDa subunit (UQCRB) of mitochondrial Complex III, resulting in inhibition of hypoxia-induced reactive oxygen species generation. Consequently, such inhibition blocks hypoxia-inducible factor activation and tumor angiogenesis in vivo, without inhibiting mitochondrial respiration. Overexpression of UQCRB or its suppression using RNA interference demonstrates that it plays a crucial role in the oxygen sensing mechanism that regulates responses to hypoxia. These findings provide a novel molecular basis of terpestacin targeting UQCRB of Complex III in selective suppression of tumor progression.
International Journal of Cancer | 2005
Eunyoung Chun; Cheol Kyu Han; Jeong Hyeok Yoon; Tae Bo Sim; Yoon Keun Kim; Ki-Young Lee
Inhibition of angiogenesis is emerging as a promising strategy for the treatment of cancer. In our study reported here, the effects of 4 highly potent methionine aminopeptidase 2 (MetAP2) inhibitors, IDR‐803, IDR‐804, IDR‐805 and CKD‐732 (designed by structure‐based molecular modeling), on angiogenesis and tumor growth were assessed. Concentrations of these inhibitors as low as 2.5 nM were able to inhibit the growth of human umbilical vein endothelial cells (HUVEC) by as much as 50%, arresting growth in the G1 stage of mitosis. An intracellular accumulation of p21WAF1/Cip1 protein was also observed. Furthermore, at higher concentrations (25 nM) of these 4 MetAP2 inhibitors, a significant induction of apoptosis was apparent in the same HUVEC cultures. As a result of these findings, the possible anticancer effects of these inhibitors were examined, utilizing the SNU‐398 hepatoma cell line. Interestingly, pretreatment with these inhibitors led to an increased number of apoptotic cells of up to 60% or more, compared to untreated controls. Moreover, utilizing an in vivo xenografted murine model, these inhibitors suppressed the growth of engrafted tumor. In conclusion, these 4 inhibitory compounds potently exert an antiangiogenic effect to inhibit the growth of cancers in vivo and could potentially be useful for the treatment of a variety of cancers.
Bioorganic & Medicinal Chemistry Letters | 2000
Cheol Kyu Han; Soon Kil Ahn; Nam Song Choi; Ryung Kee Hong; Seung Kee Moon; Hyoung Sik Chun; Sang-Joon Lee; Jung Woo Kim; Chung Il Hong; Deukjoon Kim; Jeong Hyeok Yoon; Kyoung Tai No
New fumagillin analogues were designed through structure-based molecular modeling with a human methionine aminopeptidase-2. Among the fumagillin analogues, cinnamic acid ester derivative CKD-731 showed 1000-fold more potent proliferation inhibitory activity on endothelial cell than TNP-470.
BMC Structural Biology | 2007
Jung Sue Byun; Jin Kyu Rhee; Nam Doo Kim; Jeong Hyeok Yoon; Dong Uk Kim; Eunhee Koh; Jong Won Oh; Hyun Soo Cho
BackgroundEstE1 is a hyperthermophilic esterase belonging to the hormone-sensitive lipase family and was originally isolated by functional screening of a metagenomic library constructed from a thermal environmental sample. Dimers and oligomers may have been evolutionally selected in thermophiles because intersubunit interactions can confer thermostability on the proteins. The molecular mechanisms of thermostabilization of this extremely thermostable esterase are not well understood due to the lack of structural information.ResultsHere we report for the first time the 2.1-Å resolution crystal structure of EstE1. The three-dimensional structure of EstE1 exhibits a classic α/β hydrolase fold with a central parallel-stranded beta sheet surrounded by alpha helices on both sides. The residues Ser154, Asp251, and His281 form the catalytic triad motif commonly found in other α/β hydrolases. EstE1 exists as a dimer that is formed by hydrophobic interactions and salt bridges. Circular dichroism spectroscopy and heat inactivation kinetic analysis of EstE1 mutants, which were generated by structure-based site-directed mutagenesis of amino acid residues participating in EstE1 dimerization, revealed that hydrophobic interactions through Val274 and Phe276 on the β8 strand of each monomer play a major role in the dimerization of EstE1. In contrast, the intermolecular salt bridges contribute less significantly to the dimerization and thermostability of EstE1.ConclusionOur results suggest that intermolecular hydrophobic interactions are essential for the hyperthermostability of EstE1. The molecular mechanism that allows EstE1 to endure high temperature will provide guideline for rational design of a thermostable esterase/lipase using the lipolytic enzymes showing structural similarity to EstE1.
Bioorganic & Medicinal Chemistry | 2009
Kisun Ryu; Nam Doo Kim; Seong Il Choi; Cheol Kyu Han; Jeong Hyeok Yoon; Kyoung Tai No; K. Kim; Baik Lin Seong
Hepatitis C virus (HCV) is the major etiological agent of non-A, non-B hepatitis where no effective treatment is available. The HCV NS5B with RNA-dependent RNA polymerase (RdRp) activity is a key target for the treatment of HCV infection. Here we report novel NS5B polymerase inhibitors identified by virtual screening and in vitro evaluation of their inhibitory activities. On the basis of a newly identified binding pocket of NS5B, distinct from the nucleotide binding site but highly conserved among various HCV isolates, we performed virtual screening of compounds that fit this binding pocket from the available chemical database of 3.5 million compounds. The inhibitory activities of the in silico selected 119 compounds were estimated with in vitro RdRp assay. Three compounds with IC50 values of about 20 microM were identified, and their kinetic analyses suggest that these compounds are noncompetitive inhibitors with respect to the ribonucleotide substrate. Furthermore, the single-point mutations of the conserved residues in the binding pocket of NS5B resulted in the significant decrease of the RdRp activity, indicating that the binding pocket presented here might be important for the therapeutic intervention of HCV. These novel inhibitors would be useful for the development of effective anti-HCV agents.
Bioorganic & Medicinal Chemistry Letters | 2008
Young Hoon Kim; Hojin Choi; Jaekwang Lee; In-Chang Hwang; Seung Kee Moon; Soo-Jin Kim; Hong Woo Lee; Dai Sig Im; Sung Sook Lee; Soon Kil Ahn; Sang Woong Kim; Cheol Kyu Han; Jeong Hyeok Yoon; Kyung Joo Lee; Nam Song Choi
In an effort to minimize side effects associated with low selectivity against PDE isozymes, we have successfully identified a series of 6,7,8-substituted quinzaolines as potent inhibitors of PDE5 with high level of isozyme selectivity, especially against PDE6 and PDE11. PDE5 potency and isozyme selectivity of quinazolines were greatly improved with substitutions both at 6- and 8-position. The synthesis, structure-activity relationships and in vivo efficacy of this novel series of potent PDE5 inhibitors are described.
Leukemia Research | 2009
Dongho Kim; Dong-Wook Kim; Byung-Sik Cho; Hyun-Gyung Goh; Soo Hyun Kim; Wan-Seok Kim; Jeong Lee; Il-Young Kweon; Sa-Hee Park; Jeong Hyeok Yoon; Nam Doo Kim; Haarin Chun
Sequential treatment with different tyrosine kinase inhibitors (TKIs) is one of the strategies for handling chronic myeloid leukemia (CML) in which dynamic change in Bcr-Abl kinase domain mutation is often an obstacle faced during TKI therapy. Here we report successful sequential therapy with different TKIs for the CML patient harboring V299L and E459K compound mutations. Molecular monitoring including quantitative analysis of BCR-ABL transcript level and mutation analysis were performed regularly for successful treatment. Additionally a drug-target complex was structurally modeled to investigate influence of amino acid substitutions on drug resistance, and to choose alternative TKI in sequential therapy, suggesting protein structural modeling can be useful approach in selecting alternative TKIs.
Proteomics Clinical Applications | 2009
Hye Jin Jung; Joong Sup Shim; Jungchan Park; Hyun-Joon Ha; Jung Ho Kim; Joong-Gon Kim; Nam Doo Kim; Jeong Hyeok Yoon; Ho Jeong Kwon
IHY‐153 (2‐(2,5‐difluorobenzyl)‐3,4‐dihydro‐5‐(10‐hydroxydecyl)‐6‐methoxy‐1‐undecylisoquinolinium bromide) was recently discovered as a small molecule that potently inhibits proliferation of tumor cells by inducing cell‐cycle arrest at G0‐G1 phase. To investigate the basis of anti‐proliferative activity of IHY‐153, cellular binding proteins of biotinyl‐IHY‐153 were screened using T7 phage displayed human cDNA libraries. Calmodulin‐expressing phage specifically bound to immobilized IHY‐153 in a Ca2+‐dependent manner. The interaction between IHY‐153 and Ca2+/CaM was validated through phage competition binding assays, surface plasmon resonance analysis, and molecular modeling. IHY‐153 induced sustained phosphorylation of extracellular signal‐regulated kinase (ERK) 1/2 and subsequently increased p21WAF1 expression in colon cancer cells. These results demonstrate that IHY‐153, a novel small molecule, targets Ca2+/CaM and indicate that this compound functions as an anti‐proliferative agent by influencing Ca2+/CaM‐dependent signal transduction.
Biochemical and Biophysical Research Communications | 2002
Ki-Young Lee; Jeong Hyeok Yoon; Mihyung Kim; Sujin Roh; Yeon-Sook Lee; Baik-Lin Seong; Kilhyoun Kim
The Src homology 3 (SH3) domain plays a crucial role in protein-protein interactions during intracellular signal transduction. Blocking the SH3-mediated protein binding may inhibit the corresponding signal transduction, and thus, block the cellular functions. In this study, a peptide that specifically binds to SH3 domain could be introduced into the intracellular region when the peptides were conjugated with dipalmitic acid and appeared to disturb intracellular signaling. The dipalmitoyl peptide appeared to inhibit the phosphorylation of ZAP-70, Lck, and T-cell antigen receptor zeta in Jurkat. Mobilization of the intracellular free calcium induced by anti-CD3 antibody was reduced after treatment with the dipalmitoyl peptide. It was also observed that the dipalmitoyl peptide inhibited cancer cell growth both in vitro and in vivo. These results suggest that the dipalmitoyl peptide that presumably disturbs SH3-mediated signal transduction may have a potent anti-proliferative activity, which would be useful as a potential anti-tumor agent.
Chemical Physics Letters | 2000
Ky-Youb Nam; Jeong Hyeok Yoon; Kyoung Tai No
Abstract To illuminate the behavior of ion pairs in aqueous solution, both ab initio SCRF MO calculation and MD simulation were performed. The free energy difference of each system was decomposed into contributing components in order to investigate the role of the water in aqueous solution. In aqueous solution, the dominant component contributing to the ion pair stability, is not a solute–solute interaction, but an ion pair–water interaction and the energy change that originated from the rearrangement of the water molecules around the ion pair.